Last updated: July 27, 2026
Promethazine hydrochloride is a long-established, off-patent small-molecule antihistamine used across antiemetic, sedation, allergy, and adjunct indications. The drug’s clinical development footprint is limited and largely rotational (formulation, bioequivalence, and use expansions) rather than late-stage registrational programs. Market growth is expected to track population, chronic use in select care settings, and substitution cycles driven by generics and formulary access rather than by new branded launches.
Is promethazine hydrochloride still in clinical trials?
Yes, but primarily in low-risk categories: bioequivalence studies for generic products, formulation optimization (oral, rectal, topical where applicable), and small, investigator-led studies focused on symptom control in specific clinical contexts. Large Phase 3 registrational trials are not a dominant feature for the compound because the active substance is widely generically available and not tied to a single modern, branded NDA/505(b)(2) development program.
What kinds of promethazine hydrochloride clinical trials are most common?
- Bioequivalence and pharmacokinetic (PK) studies for generic tablets, syrups, and sometimes oral solutions and suppositories.
- Formulation studies that test alternative excipient systems, taste-masking, release profiles, and stability.
- Adjunct clinical studies that evaluate symptom outcomes (nausea control, sedation, allergic symptom scores) rather than new disease-modifying endpoints.
What trial phases are most likely to be reported?
- Early-phase PK/BE (Phase 1 or “Phase 1/2” label usage depending on registry conventions).
- Pilot or small randomized trials (often not labeled as Phase 3 due to off-patent status and non-registrational intent).
- Trials tied to supportive care protocols (antiemetic pathways, anesthesia premedication studies, emergency department symptom protocols).
What is the latest clinical trials signal for promethazine hydrochloride?
The most actionable “latest signal” is not a single late-stage readout, but the ongoing presence of:
- Generic BE studies across multiple countries (frequent updates because manufacturers must support supply and regulatory listings).
- Protocol-based studies in nausea and sedation settings, where the drug remains a standard comparator or a background therapy.
Because promethazine hydrochloride is not commonly the subject of large corporate late-stage development, the clinical-trials landscape is best interpreted as regulatory lifecycle activity and supportive-care protocol research, not as a pipeline catalyst.
How to interpret trial listings for an off-patent drug
- A “recent trial” often indicates manufacturing/reformulation rather than a new clinical claim.
- A trial’s registration does not automatically imply FDA approval of a new indication or a new dosage form unless linked to a specific regulatory submission.
What indications use promethazine hydrochloride in current practice?
Promethazine hydrochloride is used for:
- Nausea and vomiting (antiemetic).
- Allergic symptoms (histamine H1 receptor antagonist effects).
- Sedation and premedication in some settings (as part of symptom control workflows).
- Motion sickness and related antiemetic supportive care uses depending on local labeling and guideline adoption.
- Adjunct therapy in treatment pathways where antihistamine-mediated symptom reduction is relevant.
Does promethazine hydrochloride have new-label clinical intent today?
Most new “intent” is incremental: combination regimens, protocol positioning, dose form changes, or comparative effectiveness against other antiemetics rather than brand-new disease categories.
What is the Orange Book status of promethazine hydrochloride?
Promethazine hydrochloride is widely available as generic. Orange Book “exclusivity” for the underlying active ingredient is typically absent or expired because the substance is long out of patent term. Practical Orange Book relevance now centers on:
- Remaining patents that may cover specific formulations or dosing forms for particular listed products (if any exist for a given NDA).
- Exclusivity tied to specific product-specific changes, if a manufacturer obtained it for a formulation, process, or indication.
The operational takeaway: there is no dominant, compound-level regulatory exclusivity barrier preventing generics in the U.S., and market access is driven by supply, labeling, and formulation competitiveness.
How many patents protect promethazine hydrochloride in the US?
For the active ingredient itself, the patent estate is generally not a limiting factor because promethazine hydrochloride is a legacy molecule. Any continuing patent constraints, if present, are usually:
- Product-specific formulation or process patents
- Dosing form specific patents (e.g., sustained release variants if they exist for a given sponsor)
- Method-of-use patents tied to narrow claims, though these are less common for an off-patent compound used broadly
In practice, the dominant market reality is that multiple suppliers already compete with the same or closely equivalent labeled active ingredient and dosing forms.
What patent litigation affects promethazine hydrochloride?
Ongoing, compound-level patent litigation is not a major theme for promethazine hydrochloride, given:
- Broad generic availability
- Lack of a single modern branded formulation with a concentrated patent estate
If litigation occurs, it tends to be:
- Product-specific disputes involving a particular formulation or dosage form
- Settlement-driven Resolution for a discrete generic entrant rather than a wave against the active ingredient
What generic entry risks exist for promethazine hydrochloride?
For most markets, generic entry risk is low because:
- The active ingredient is widely used and easily manufactured at scale
- Regulatory pathways focus on BE and quality, not on navigating a dominant patent wall
The higher-risk factors are operational:
- Supply chain constraints for API and key excipients
- Variability in bioequivalence acceptance across formulations
- Labeling and REMS or safety communications that may differ by manufacturer (where applicable)
How does promethazine hydrochloride compare with other antiemetics by competition and forecast?
In antiemesis and sedation workflows, promethazine hydrochloride competes with:
- Other antihistamine antiemetics (where used)
- Serotonin (5-HT3) receptor antagonists
- Dopamine antagonists
- Other classes depending on setting (ED, inpatient, outpatient)
Market share depends on:
- Guideline positioning
- Formulary adoption
- Safety profile preferences and dosing convenience
- Availability and price compression due to generics
Forecast implication: promethazine hydrochloride’s growth is more likely to be volume-and-substitution driven than “share capture” from newer classes, unless a protocol shift increases use.
What is the market size for promethazine hydrochloride and how is it growing?
Promethazine hydrochloride is an established, multi-manufacturer commodity-like generic. Market value is driven by:
- Unit volume (prescriptions, hospital administration)
- Pricing dynamics (tending toward low-margin price compression)
- Formulary usage in inpatient and symptom-management settings
A precise market-size number depends on the data vendor category definitions (e.g., “antiemetics” vs. “antihistamines,” “promethazine” include salt variants, and dosage forms included). The forecast for the drug in aggregate terms is:
- Steady demand
- Modest value growth
- Lower long-term price realization risk typical of mature generics
- More upside from volume retention in hospital formularies and from new generic entrants where supply increases
Who are the key suppliers of promethazine hydrochloride?
Key suppliers are typically established generics and large Indian/European generic manufacturers, along with U.S. generic houses. The competitive set changes by dosage form:
- Tablets vs syrups vs suppositories can have different dominant suppliers based on manufacturing capacity and BE approvals
- Hospital distribution also shifts which NDCs are most used
Market projection implication: price competition is usually highest where multiple AB-rated products exist and where hospitals can standardize purchasing by NDC and unit economics.
How do formulation types affect market share and pricing?
Promethazine hydrochloride’s commercial performance differs by dosage form:
- Oral forms often dominate outpatient and outpatient symptom relief.
- Injectables (where marketed in a given region) can be more protocol-dependent for inpatient settings.
- Rectal forms may retain niche usage in pediatric or home care when swallowing is difficult.
Pricing is typically lowest for the most mature forms with the widest AB coverage, while niche forms can hold higher pricing due to fewer alternative manufacturers.
Clinical pipeline vs lifecycle: what is likely to drive demand through 2030?
For promethazine hydrochloride, demand drivers through 2030 are predominantly lifecycle:
- Consistent symptom-management use in care pathways
- Generic volume stability tied to demographic and care-pattern factors
- Switching among competing antiemetics that can either protect or erode volume
- Formulary updates that may favor or disfavor first-line use of sedating antiemetics
A late-stage pipeline driver is unlikely to be the primary growth mechanism.
Market forecast for promethazine hydrochloride (2026–2035)
Base case
- Volume: low-to-moderate growth driven by stable prescribing and inpatient demand, with fluctuations due to antiemetic guideline preferences.
- Value: modest gains with sustained price compression.
- Competition: stable to slightly increasing due to ongoing BE-based entry and new NDC launches.
Downside case
- Higher preference for non-sedating antiemetics in institutional protocols.
- Tightened formulary controls due to safety considerations and sedation risk.
- API supply disruptions that temporarily constrain production and cause short-term volatility.
Upside case
- Expanded use in specific supportive-care protocols where promethazine remains cost-effective and clinically accepted.
- Manufacturing expansion increases availability, preventing stock-outs that can lose volume to competitors.
Regulatory and compliance outlook: what issues could affect promethazine hydrochloride supply?
Regulatory dynamics for an off-patent drug generally revolve around:
- cGMP compliance and quality system maturity
- BE re-registrations and post-approval changes
- Safety labeling consistency across generic manufacturers
- Distribution qualification for hospital systems
In markets where approvals are numerous and manufacturing dispersed, supply reliability and batch consistency can become the principal differentiator.
Key commercial takeaways for investors, licensors, and litigators
- Promethazine hydrochloride is best treated as a mature, competitive generics product with regulatory lifecycle activity rather than a patent-driven R&D opportunity.
- The “clinical trials update” is mostly regulatory evidence generation (PK/BE) and supportive-care research.
- The primary commercial levers are NDC coverage breadth, manufacturing capacity, formulation differentiation, and hospital contracting.
- Patent and litigation activity is typically product-specific and not a barrier to entry in the broad sense.
Key Takeaways
- Clinical activity exists, but it is mostly BE/formulation and supportive-care research, not a late-stage registrational pipeline.
- Patent and exclusivity barriers for the active ingredient are generally not binding; competition is structurally intense.
- Market growth is expected to be steady in volume terms with modest value expansion under ongoing price pressure.
- Commercial outcomes depend more on supply execution and formulary positioning than on new clinical differentiation.
FAQs
- Why do bioequivalence trials keep showing up for promethazine hydrochloride even though it is off-patent?
- Which dosage forms of promethazine hydrochloride tend to have the most AB-rated competition?
- How do hospital antiemetic protocols typically affect promethazine hydrochloride volume versus 5-HT3 or dopamine antagonists?
- What are the most common regulatory filing routes used for generic promethazine hydrochloride in the US?
- What supply-chain or manufacturing constraints most often drive NDC shortages for generic antihistamine injectables or syrups?
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
- ClinicalTrials.gov. Promethazine hydrochloride studies (search results by drug name). U.S. National Library of Medicine.
